8-K: ACELYRIN Announces Positive Phase 1/2 Data for Lonigutamab in Thyroid Eye Disease

ACELYRIN's lonigutamab, a subcutaneous anti-IGF-1R antibody, demonstrated positive proof-of-concept data in a Phase 1/2 trial for thyroid eye disease, showing rapid improvements in key clinical measures.

Summary

• ACELYRIN, INC. announced positive results from a Phase 1/2 trial of lonigutamab for thyroid eye disease (TED).
• Lonigutamab is a subcutaneously delivered antibody targeting the IGF-1R, a validated mechanism for treating TED.
• The trial showed rapid improvements in proptosis and clinical activity score (CAS) within three weeks of the first dose.
• In Cohort 1, 50% of patients on lonigutamab achieved a proptosis response, compared to 0% on placebo.
• 100% of patients in Cohort 1 on lonigutamab achieved a CAS response, compared to 0% on placebo.
• In Cohort 2, 67% of patients achieved a proptosis response and 83% achieved a CAS response.
• The drug was well-tolerated with no reports of hyperglycemia, hearing impairment, or serious adverse events.
• A Phase 2b/3 trial is planned to start in the second half of 2024.
• The company will not hold a fiscal year 2023 earnings call, instead announcing results in a press release and 10-K filing by April 1, 2024.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with a favorable safety profile, suggesting a strong potential for the drug. The planned Phase 2b/3 trial further reinforces the positive outlook.

Positives

• Lonigutamab showed rapid and clinically meaningful improvements in proptosis, CAS, and diplopia compared to placebo.
• The subcutaneous administration of lonigutamab appears to have a favorable safety profile compared to intravenous therapies.
• The drug was well-tolerated with no serious adverse events reported.
• The results support the hypothesis that lonigutamab can optimize benefit-risk by enabling longer-term subcutaneous dosing.
• The company plans to initiate a Phase 2b/3 trial in the second half of 2024.

Negatives

• The data is preliminary and based on a small group of patients.
• The study is still ongoing, and further data is needed to confirm these results.

Risks

• Future results could differ materially and adversely from early clinical data.
• The successful completion of development and regulatory activities is not guaranteed.
• There are risks and uncertainties associated with the development of the product candidate.

Future Outlook

The company plans to initiate a Phase 2b/3 trial in the second half of 2024, which is intended to be the first of two registrational trials for lonigutamab in TED.

Management Comments

• Shao-Lee Lin, MD, PhD, Founder and CEO of ACELYRIN, stated that the data supports the hypothesis that lonigutamab has the potential to optimize benefit-risk by enabling longer-term subcutaneous dosing.
• Shoaib Ugradar, MD, noted that the data suggests a clinically meaningful response in patients as early as 3 weeks after a single subcutaneous dose of lonigutamab and that the safety profile may be favorable compared to standard of care.

Industry Context

This announcement is significant as it presents the first clinical data for a subcutaneous anti-IGF-1R therapy demonstrating clinical benefit in thyroid eye disease, potentially offering a more convenient and safer alternative to existing treatments.

Comparison to Industry Standards

• The document references Teprotumumab, a standard of care for TED, noting a 21% placebo-adjusted rate at 6 weeks and 39% at 24 weeks for proptosis response.
• Lonigutamab showed a 50% proptosis response in Cohort 1 and 67% in Cohort 2 at 6 weeks, suggesting a potentially faster and more effective response than Teprotumumab.
• The subcutaneous delivery of lonigutamab is a key differentiator compared to the intravenous administration of Teprotumumab, potentially offering a more convenient treatment option.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results.
• Patients with thyroid eye disease may benefit from a new, potentially more effective and convenient treatment option.
• The company's employees are likely to be motivated by the positive progress of the drug development.

Next Steps

• A Phase 2b/3 trial is planned to be initiated in the second half of 2024.
• Further data from the ongoing trial will be presented at future scientific meetings.
• The company will announce its financial results in a press release and file the related 10-K report no later than April 1, 2024.

Key Dates

Keywords

Lonigutamab, Thyroid Eye Disease, TED, IGF-1R, Subcutaneous, Clinical Trial, Proptosis, CAS, Diplopia, Monoclonal Antibody, Autoimmune Disease